Dyne Therapeutics

$11.00 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Dyne Therapeutics

Dyne Therapeutics Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases. The Company’s FORCE platform therapeutics consists of an oligonucleotide payload that it designs to target the genetic basis of the disease. With its FORCE platform, the Company has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that it attaches to its Fab using the linker. Its DM1 program is focused on the development of a potentially disease-modifying treatment for DM1.

Stock Analysis

last close $11.44
1-mo return 35.5%
3-mo return 49.7%
avg daily vol. 186.28T
52-week high 19.24
52-week low 4.3
market cap. $592M
forward pe -
annual div. -
roe -39.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe